GLP-1 Market
LLY $1152.44 ▲ +1.3% NVO $43.19 ▲ +3.5% PFE $27.64 ▲ +0.7% VKTX $29.36 ▼ -0.5% KLRA $12.92 ▲ +1.7% GPCR $35.10 ▼ -1.1% RHHBY $54.60 ▼ -1.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Elamipretide

Company
Stealth BioTherapeutics Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 18, 2026

Find a Clinical Trial Near Me

See recruiting studies for Elamipretide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07275424

    Study of Healthy Aging and Physical Function With Elamipretide

    Not yet reported David Marcinek 30 participants Est. completion 2026-04-15 1 site
    Other conditions: Aging, Healthy
    View official trial listing →
  • Recruiting NCT NCT07531251

    Clinical Trial in Patients With Barth Syndrome- 4TAZPower

    Not yet reported Stealth BioTherapeutics Inc. 48 participants Est. completion 2029-11-30 3 sites
    Other conditions: Barth Syndrome
    View official trial listing →
  • Completed NCT NCT01572909

    Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events

    Not yet reported Stealth BioTherapeutics Inc. 300 participants Est. completion 2015-02 30 sites
    Other conditions: Reperfusion Injury, STEMI
    View official trial listing →
  • Terminated NCT NCT01755858

    Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery

    Not yet reported, Not yet reported Stealth BioTherapeutics Inc. 16 participants Est. completion 2016-05 1 site
    Other conditions: Renal Artery Obstruction, Hypertension, Renovascular, Ischemia Reperfusion Injury
    View official trial listing →
  • Completed NCT NCT02245620

    A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly

    Not yet reported Stealth BioTherapeutics Inc. 41 participants Est. completion 2016-07-06 1 site Stand-alone
    Other conditions: Skeletal Muscle Mitochondrial Dysfunction in the Elderly
    View official trial listing →
  • Completed NCT NCT02367014

    Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy

    Not yet reported, Not yet reported Stealth BioTherapeutics Inc. 36 participants Est. completion 2016-04 4 sites Stand-alone
    Other conditions: Mitochondrial Myopathy
    View official trial listing →
  • Completed NCT NCT02653391

    A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

    Not yet reported, Not yet reported Stealth BioTherapeutics Inc. 22 participants Est. completion 2018-12 2 sites Stand-alone
    Other conditions: Fuchs' Corneal Endothelial Dystrophy (FCED)
    View official trial listing →
  • Completed NCT NCT02693119

    A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

    Not yet reported Stealth BioTherapeutics Inc. 12 participants Est. completion 2019-12 1 site Stand-alone
    Other conditions: Leber's Hereditary Optic Neuropathy
    View official trial listing →
  • Completed NCT NCT02788747

    Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

    Not yet reported Stealth BioTherapeutics Inc. 71 participants Est. completion 2017-10 15 sites Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT02805790

    Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study

    Not yet reported Stealth BioTherapeutics Inc. 30 participants Est. completion 2017-03-23 4 sites Stand-alone
    Other conditions: Primary Mitochondrial Disease
    View official trial listing →
  • Completed NCT NCT02814097

    A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction

    Not yet reported Stealth BioTherapeutics Inc. 46 participants Est. completion 2017-06-02 9 sites Stand-alone
    Heart failure
    View official trial listing →
  • Completed NCT NCT02848313

    An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

    Not yet reported Stealth BioTherapeutics Inc. 40 participants Est. completion 2018-04-10 1 site Stand-alone
    Other conditions: Age-Related Macular Degeneration
    View official trial listing →
  • Completed NCT NCT02914665

    A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

    Not yet reported Stealth BioTherapeutics Inc. 308 participants Est. completion 2017-11-27 46 sites Stand-alone
    Heart failure
    View official trial listing →
  • Terminated NCT NCT02976038

    Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

    Not yet reported Stealth BioTherapeutics Inc. 28 participants Est. completion 2020-04-09 4 sites Stand-alone
    Other conditions: Primary Mitochondrial Disease
    View official trial listing →
  • Completed NCT NCT03098797

    A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

    Not yet reported, Not yet reported Stealth BioTherapeutics Inc. 12 participants Est. completion 2021-10-11 1 site Stand-alone
    Other conditions: Barth Syndrome
    View official trial listing →
  • Terminated NCT NCT03323749

    A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

    Not yet reported Stealth BioTherapeutics Inc. 218 participants Est. completion 2020-02-10 27 sites Stand-alone
    Other conditions: Primary Mitochondrial Myopathy
    View official trial listing →
  • Completed NCT NCT03891875

    ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA

    Not yet reported Stealth BioTherapeutics Inc. 176 participants Est. completion 2022-04-14 37 sites Stand-alone
    Other conditions: Age-related Macular Degeneration
    View official trial listing →
  • Available NCT NCT04689360

    An Intermediate Size Expanded Access Protocol of Elamipretide

    Stealth BioTherapeutics Inc.
    Other conditions: Mitochondrial Diseases, Barth Syndrome
    View official trial listing →
  • Completed NCT NCT05162768

    Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

    Not yet reported Stealth BioTherapeutics Inc. 102 participants Est. completion 2024-12-04 32 sites Stand-alone
    Other conditions: Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases, Mitochondrial DNA Deletion, Mitochondrial DNA Depletion, Mitochondrial Metabolism Defect, Mitochondrial Complex I Deficiency
    View official trial listing →
  • Completed NCT NCT05168774

    FRDA Investigator Initiated Study (IIS) With Elamipretide

    Not yet reported, Not yet reported Children's Hospital of Philadelphia 20 participants Est. completion 2024-07-25 1 site Stand-alone
    Other conditions: Friedreich Ataxia
    View official trial listing →
  • Active, not recruiting NCT NCT06373731

    ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

    Not yet reported Stealth BioTherapeutics Inc. 313 participants Est. completion 2027-09 53 sites Stand-alone
    Other conditions: Age Related Macular Degeneration (ARMD)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Elamipretide, FORZINITY, elamipretide hydrochloride

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.